On 11 January, the pharmaceutical company Eli Lilly announced that its Phase II clinical trial evaluating donanemab in Alzheimer’s disease (AD) met its primary endpoint. Donanemab is an investigational antiamyloid therapy, targeting a modified form of beta amyloid called N3pG.
We continue to develop and improve our Clinical Trials Watch, which provides up-to-date accessible information on phase II and III clinical trials for dementia/Alzheimer’s treatment/prevention, and currently recruiting in Europe. In January 2021, two new Phase II trials have been added.
Federazione Alzheimer Italia has been instrumental in securing funding for Italy's national dementia plan. While the Plan has been in place since 2014, it had no associated funding. Specific funding will allow the country to start transforming objectives into concrete actions to support people with dementia.
LETHE is a personalised prediction and intervention model for early detection and reduction of risk factors causing dementia, based on AI and distributed Machine Learning. It is a four-year project funded under Horizon 2020.
Members of the European Alzheimer’s Alliance (EAA) have shown their support for the prioritisation of dementia at an EU level, following the publication of the Alzheimer Europe report, “Dementia as a European Priority – A Policy Overview”.
On 1 February, the members of the Neuronet (Efficiently Networking European Neurodegeneration Research) programme announced the launch of a pan-European Knowledge Base which brings together key information about the 18 projects of the Innovative Medicines Initiative (IMI) neurodegeneration (ND) portfolio.
This newsletter received funding under an operating grant from the European Union’s Health Programme (2014-2020).
The content of this newsletter represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.